You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Develop a Tool to Measure Bonded Joint Strength for Primary Load Bearing Aircraft Structures
SBC: LSP Technologies, Inc. Topic: AF05125To reduce weight and improve fuel efficiency, composites are being adhesively bonded into integral structural elements of aircraft at an accelerating rate. Once a bonded structure is assembled, there is no conventional NDI method available to assure that bond strength is adequate for service. The presence of weak regions in bonds can lead to disastrous failure of the structure under flight loads ...
SBIR Phase II 2017 Department of DefenseAir Force -
Peripheral nerve stimulation for amputee pain
SBC: SPR THERAPEUTICS, INC. Topic: 105AbstractThe goal of the presently proposed Commercialization Readiness PilotCRPProgram project is to prepare for commercialization of an implantable systemdeveloped in Phase IIthat is capable of delivering a novel peripheral nerve stimulationPNStherapy shown to be highly effective in treating intractable pain in a majority of amputees in previous studiesincluding Phase IApproximatelymillion indivi ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Kinetic Phenotype Discovery Informatics for Neurological Diseases
SBC: DRVISION TECHNOLOGIES LLC Topic: 101Project Summary Neurological disorders significantly outnumber diseases in other therapeutic areas and are growing in incidence faster than any other disease classesHoweverthe pharmaceutical industry has been unsuccessful in coming up with effective drugsA big factor in these failures has been a lack of adequate model systems for fundamental disease understanding affecting both diagnosis and treat ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Rapid Cure System for Nutplate Installation
SBC: CORNERSTONE RESEARCH GROUP INC Topic: AF161124Air Force platforms utilize nutplates to attach components when fasteners access is limited. Damaged nutplates require timely replacement and approved repair techniques mandate the use of certified adhesives, typically requiring a lengthy 24 hour cure at room temperature. Therefore, Air Force repair depots are faced with the difficult situation of performing high volume, timely nutplate repairs us ...
SBIR Phase II 2017 Department of DefenseAir Force -
Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents
SBC: BIOVENTURES, INC Topic: 172Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Lithium Oxyhalide Battery Separator Material
SBC: ESPIN TECHNOLOGIES, INC. Topic: MDA15027eSpin Technologies will design the scale up machine to produce novel high performance separator for lithium primary batteries. The process will be developed to produce novel separator and a variants which has the potential of a significantly higher volumetric efficiency for electrolyte storage capacity and kinetics to distribute electrolyte flow within nanoporous channel efficiently. This new sepa ...
SBIR Phase II 2017 Department of DefenseMissile Defense Agency -
Commercialization of an MRI contrast agent for differential diagnosis ofprostate cancer.
SBC: MOLECULAR THERANOSTICS, LLC Topic: NCIContact PD PILiYajuan AbstractParent GrantProstate cancer is a highly heterogeneous disease and the second most cause of cancer death of men in the USCurrent methods to assess prostate cancer risk combine prostate specific antigenPSAscreening and random prostate biopsyUnfortunatelythis strategy fails to reveal the lesion s location and does not accurately differentiate between aggressive and non a ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.
SBC: Oncoimmune Inc Topic: 102Project Summary AbstractAcute graft versus host diseaseaGVHDis a principal contributor to transplant related mortalityTRMand develops in approximatelyof recipients receiving unrelated donor hematopoietic stem cell transplantationHSCTdespite standard immunosuppressive prophylaxisThusnovel GVHD prophylaxis treatments which successfully attenuate aGVHD and related complications such as infection are ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP
SBC: PHARMAIN CORPORATION Topic: NHLBIABSTRACTThis application is seeking funding specifically for ChemistryManufacturingand ControlCMCof scale up production of long acting atrial natriuretic peptidedANPand its protected graft co polymerPGCexcipient for use in heart failureHFtreatmentThe extrinsic merit of this project will be the availability of cGMP grade PGC for use in prolonging the half life of various peptide drugs that are in p ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
A Novel Tolerance Therapeutic for Treating Multiple Sclerosis
SBC: VIRTICI LLC Topic: NIAIDOur goal is to develop VTC MSas a novel tolerance inducing therapeutic to treat Multiple SclerosisMSMS is the most common demyelinating disorder of the Central Nervous SystemCNSaffecting approximatelymillion people worldwide andin the US aloneCurrent and developing treatment of MS relies mainly on immuno suppression and modulation to reduce inflammatory symptoms creating a significant need for new ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health